Vertex (VRTX) board member receives deferred stock unit award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Garber Alan M reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Alan M. Garber received a grant of 33.898 deferred stock units, each tied to one share of common stock. The units were valued at $442.50 per share and are payable in common stock upon the earliest of his board service ending, a change of control, or his disability or death. This represents routine equity-based board compensation rather than an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Garber Alan M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	33.898	$442.50	$15K

Holdings After Transaction: Deferred Stock Units — 33.898 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Deferred stock units granted: 33.898 units Grant reference price: $442.50 per unit Total units held after grant: 33.898 units +1 more

4 metrics

Deferred stock units granted 33.898 units Award to director Alan M. Garber on 2026-04-15

Grant reference price $442.50 per unit Value per deferred stock unit

Total units held after grant 33.898 units Total deferred stock units following transaction

Underlying common shares 33.898 shares Each unit represents one share of common stock

Key Terms

Deferred Stock Units, change of control, common stock

3 terms

Deferred Stock Units financial

"Each deferred stock unit represents one share of common stock"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

change of control financial

"upon the earliest to occur of (i) termination ... (ii) a change of control of our company"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

common stock financial

"is paid out in common stock upon the earliest to occur"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

04/17/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garber Alan M

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Stock Units	⁽¹⁾	04/15/2026		A		33.898		⁽¹⁾	⁽¹⁾	Common Stock	33.898	$442.5	33.898	D

Explanation of Responses:

1. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did VRTX director Alan Garber report on this Form 4?

Alan M. Garber reported receiving 33.898 deferred stock units of Vertex Pharmaceuticals as a compensation grant. Each unit corresponds to one share of common stock, valued at $442.50 per share, and will be settled in stock when specific service or control events occur.

Is Alan Garber’s VRTX Form 4 transaction a stock purchase or sale?

The Form 4 shows an acquisition as a grant, not a market trade. Garber received 33.898 deferred stock units as compensation, rather than buying or selling shares in the open market, so it reflects routine director pay rather than an investment decision.

When will Alan Garber’s Vertex deferred stock units be paid out?

The deferred stock units are paid in common stock upon the earliest of three events. These are termination of his board service, a change of control of Vertex Pharmaceuticals, or his disability or death, according to the footnote disclosure.

How many Vertex shares does Alan Garber hold through this deferred stock unit award?

After the reported grant, Garber holds 33.898 deferred stock units, each representing one share of Vertex common stock. The total position in this award is therefore 33.898 share-equivalents, all held as deferred compensation rather than currently issued common shares.

What is the implied value of Alan Garber’s new VRTX deferred stock units?

The grant covers 33.898 deferred stock units at an indicated value of $442.50 per share. This implies a compensation value of roughly $15,000, highlighting a modest, routine-sized equity award tied to his service on Vertex’s board of directors.